TRANS GENIC GROUP INC. (2342) Income statement

Market cap
¥3.6B
P/E ratio
23.8x
Transgenics Group supports drug development through specialized lab services like genetically modified mice production and pharmaceutical testing, while also providing business consulting and importing various products from electrical equipment to tableware.
2012/032013/032014/032015/032016/032017/032018/032019/032020/032021/032022/032023/032024/032025/032026/03
Revenue6087041,6181,9592,2902,3033,6018,67511,04711,04612,57711,43013,08313,00513,174
Revenue growth (%)--
Cost of revenue---1,3021,6181,5542,7797,1769,2678,2698,7419,43510,83410,83810,741
Gross profit---6576737498221,4981,7802,7773,8361,9952,2492,1672,434
Gross margin (%)---
Operating margin (%)---
Operating expenses ---6336225957621,2281,6061,8841,9992,0202,1602,4262,296
Operating income ---2450154612701748931,837-2589-260137
Income before tax -120-32-1229198814256958921,819199108-320118
Pretax margin (%)-19.8-4.5-7.60.50.83.80.430.98.114.51.70.8-2.50.9
Provision for income taxes----341-6119115390810839415-110
Effective tax rate (%)---
Net income -16219-10218158121202-4415461,876-4104-1,090-484
Earnings per share-12.062.09-8.391.291.055.631.4111.95-25.3831.45109.52-24.320.24-65.51-4.64
Diluted EPS-2.08-1.291.055.621.3911.91-31.45109.31----
Dividend payout ratio (%)-------------
Dividend per share---------3653--
AI Chat